Nature research paper: Therapy-induced APOBEC3A drives evolution of persistent cancer cells
A.N.H. has received grants/research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech and Scorpion Therapeutics; and has served as a compensated consultant for Engine Biosciences, Nuvalent, Oncovalent, TigaTx and Tolremo Therapeutics. C.J.O. has received research support from Gilead, Scorpion Therapeutics and eFFECTOR Therapeutics. G.G.
has served as a compensated consulted for C4 Therapeutics. R.B. has served as a compensated consultant for Pfizer and Health Advances. Y.E.M. has served as a compensated consultant for Foresee Genomics. Z.P.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
The Best Red Light Therapy Devices (and Why They Work)This FDA-approved treatment helps improve skin health and vitality while decreasing the appearance of acne, scars and signs of aging. RSRecommends
Consulte Mais informação »
Botox-encoded mRNA therapy that makes tumors kill themselvesLipid nanoparticle injection loaded with toxin mRNA can revolutionize cancer treatment as it promises a safer and better alternative to chemotherapy.
Consulte Mais informação »
13 LED Light-Therapy Masks That Are Worth the InvestmentWe rounded up the best LED light-therapy masks to purchase in 2023
Consulte Mais informação »
Arizona House leader says Hobbs' order against 'conversion therapy' is illegalTop House Republican says Democratic Gov. Katie Hobbs' order appears to violate the rights of parents to make decisions for their children.
Consulte Mais informação »
Former brain injury patient turned bodybuilder donates more than $30K for therapy scholarshipsKel Mabatah was attacked during a visit to see family in Nigeria in 2014. Doctors initially told the former Tennis star he may never walk or talk again, but is now helping other patients like him rehabilitate through a generous donation.
Consulte Mais informação »
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results - Nature MedicineProphylactic subcutaneous administration of anakinra, an IL-1 receptor inhibitor, reduced severe immune effector cell-associated neurotoxicity syndrome incidence in patients with relapsed or refractory large B-cell and mantle cell lymphoma treated with anti-CD19 chimeric antigen receptor (CAR) T cells.
Consulte Mais informação »